# LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

> **NCT02450903** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** LDK378

## Key facts

- **NCT ID:** NCT02450903
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-21
- **Primary completion:** 2017-07-31
- **Final completion:** 2018-05-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450903, "LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02450903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*